A Study of Docetaxel in Combination With Capecitabine in Stomach and Esophagus Cancers

Cancer Clinical Trial

Official title:

A Phase II Study of Weekly Docetaxel (Taxotere®) in Combination With Capecitabine (Xeloda) in Advanced Gastric and Gastro-Esophageal Adenocarcinomas.

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00177255
• Other study ID #: 04-026
• Status: Terminated
• Phase: Phase 2
• First received: September 12, 2005
• Last updated: January 10, 2016
• Start date: April 2005
• Est. completion date: December 2008

Study information

• Verified date: January 2016
• Source: University of Pittsburgh
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

This is a phase II study that will investigate weekly dosing of docetaxel in combination with capecitabine in advanced gastric and gastro-esophageal adenocarcinomas.

Description:

This is a phase II study that will investigate weekly dosing of docetaxel in combination with capecitabine in advanced gastric and gastro-esophageal adenocarcinomas. Docetaxel 30mg/m2 will be administered on days 1 and 8 of each cycle and capecitabine 825mg/m2 bid (total daily dose 1650mg/m2) will be administered orally for 14 days (days 1-14) of each cycle. Each cycle is 21 days. Subjects will receive unlimited cycles of docetaxel and capecitabine until there is evidence of disease progression or unacceptable side effects.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 40
• Est. completion date: December 2008
• Est. primary completion date: December 2008
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Have histologically or cytologically confirmed locally advanced (unresectable) or metastatic adenocarcinoma of gastric, gastro-esophageal, or esophageal origin.

2. Must have measurable or evaluable disease.

3. Received adjuvant therapy are eligible if adjuvant therapy was given = 6 months prior to the diagnosis of metastatic disease.

4. Life expectancy greater than 12 weeks.

5. ECOG performance status < 2.

6. Adequate organ and marrow function.

7. Preexisting peripheral neuropathy if present must be grade 0 or 1.

8. Women and men of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for at least 3 months thereafter. Postmenopausal women must have been amenorrheic for at least 12 months to be considered of non-childbearing potential

Exclusion Criteria:

1. No chemotherapy or radiotherapy within 4 weeks

2. Not receiving any other investigational agents or participate in any investigational drug study within 4 weeks preceding the start of study treatment.

3. Patients with known brain metastases shall be excluded from this clinical trial

4. Patients with evidence or history of uncontrolled seizures, central nervous system disorders or psychiatric disability judged by the investigator to be clinically significant that precludes informed consent or interferes with the compliance of oral drug intake will also be excluded.

5. History of severe hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate 80.

6. History of allergic reactions attributed to compounds of similar chemical or biologic composition to docetaxel, capecitabine or 5-FU.

7. Uncontrolled intercurrent illness

8. Pregnant or breast feeding women are excluded from this study

9. Inability to swallow tablets or those who have malabsorptive symptoms will be excluded.

10. HIV-positive patients receiving combination anti-retroviral therapy are excluded from the study because of possible pharmacokinetic interactions with docetaxel or capecitabine.

11. Prior use of docetaxel or capecitabine is not allowed ( Prior 5FU therapy is allowed).

12. Treatment for other carcinomas within the last five years, except cured non-melanoma skin and treated in-situ cervical cancer.

13. Major surgery ( i.e laparotomy, line placement is not considered major surgery)within 4 weeks of the start of study treatment, without complete recovery.

14. Known, existing uncontrolled coagulopathy.

15. Patients on anticonvulsants that are metabolized via P450 3A4 pathway.

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Cancer

Intervention

Drug:
• Docetaxel
Docetaxel 30 mg/m2 will be administered as a 30-minute infusion on days 1 and 8. Each cycle will consist of 21 days. Cycle 2 will begin on day 22.
• Capecitabine
Capecitabine 825 mg/m2 bid (total daily dose 1650 mg/m2) will be administered orally for 14 days (days 1-14). Each cycle will consist of 21 days. Cycle 2 will begin on day 22.

Locations

Country	Name	City	State
United States	University of Pittsburgh Medical Center	Pittsburgh	Pennsylvania

Sponsors (3)

Lead Sponsor	Collaborator
University of Pittsburgh	Aventis Pharmaceuticals, Roche Pharma AG

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall Survival	The time interval between the date on which a patient first received protocol treatment and the documented date of death.	2 years	No
Secondary	Overall Response Rate	The number of responders (complete responders + partial responders) divided by the number of evaluable patients.	Every 2 cycles (6 weeks)	No